Mylan NV (NASDAQ: MYL) a United States-based generic and specialty pharmaceuticals company, and Fujifilm Kyowa Kirin Biologics Co Ltd, a company established by FUJIFILM Corporation and Kyowa Kirin Co Ltd, has received approval from the United States Food and Drug Administration (FDA) for its Hulio (adalimumab-fkjp), a biosimilar to AbbVie's Humira (adalimumab), intended for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis (four years and older), ankylosing spondylitis, adult Crohn's disease, psoriatic arthritis, ulcerative colitis and plaque psoriasis, offered in both prefilled syringe and auto-injector presentations, it was reported on Thursday.
The product's approval was based on a comprehensive analytical, preclinical and clinical program. Fujifilm Kyowa Kirin Biologics conducted the Phase three clinical study, ARABESC that indicated no clinically meaningful differences in terms of safety, efficacy and immunogenicity compared with the reference product, Humira, in rheumatoid arthritis patients.
Both firms collaborated in 2018 for the commercialisation of Hulio in Europe, and Mylan has commercialised the product in several countries across the region.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients